Home World News FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated... World News FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer By Ogkologos - October 28, 2026 199 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the SERENA-6 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Woman Creates Non-Toxic Nail Polish Brand After Her Mom’s Breast Cancer... November 20, 2020 Four Different Doctors Misdiagnosed Woman’s Breast Pain Because “Breast Cancer Doesn’t... September 8, 2020 Husband Turns Wife’s Inspiring Poem for Her Daughters into a Book... February 25, 2020 Treatment Benefit with Quizartinib, a Potent and Specific FLT3 Inhibitor for... May 2, 2023 Load more HOT NEWS Off Target: Investigating the Abscopal Effect as a Treatment for Cancer Newly Discovered ‘Don’t Eat Me’ Signal May be a Target for... Lucky 13-A Male Breast Cancer Story Patient Guide in Colorectal Cancer Now Available in Bulgarian
